Interactions between D1 and D2 dopamine receptor family agonists and antagonists: The effects of chronic exposure on behavior and receptor binding in rats and their clinical implications

Journal of Neural Transmission

Volumn 104, Issue 4-5, 1997, Pages 341-362

  Braun, A R ^a   Laruelle, M ^c   Mouradian, M M ^b  

^a NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS   (United States)

^b NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^c YALE UNIVERSITY   (United States)

Author keywords

Behavior chronic stereotypy; Catalepsy; D1D2 dopamine receptor; Locomotion; Supersensitivity

Indexed keywords

2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; APOMORPHINE; DOPAMINE 1 RECEPTOR; DOPAMINE 1 RECEPTOR BLOCKING AGENT; DOPAMINE 1 RECEPTOR STIMULATING AGENT; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE 2 RECEPTOR STIMULATING AGENT; METOCLOPRAMIDE; QUINPIROLE; RECEPTOR SUBTYPE;

ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CATALEPSY; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DRUG TOLERANCE; LOCOMOTION; MALE; MENTAL DISEASE; NEUROPSYCHIATRY; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR BINDING; RECEPTOR DENSITY; STEREOTYPY;

ANIMALS; APOMORPHINE; BEHAVIOR, ANIMAL; CATALEPSY; CORPUS STRIATUM; DOPAMINE AGENTS; DRUG INTERACTIONS; MALE; MOTOR ACTIVITY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2; STEREOTYPED BEHAVIOR;

EID: 0030865602     PISSN: 03009564     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01277656     Document Type: Article

References (70)

1. Arnt J, Perregaard J (1987) Synergistic interaction between dopamine D-1 and D-2 receptor agonists: circling behaviour of rats with hemitransection. Eur J Pharmacol 143: 45-53
2. Arnt J, Hyttel J, Perregaard J (1987) Dopamine D-1 receptor agonists combined with the selective D-2 agonist quinpirole facilitate the expression of oral stereotyped behaviour in rats. Eur J Pharmacol 133: 137-145
3. Bedard PJ, Gomez-Mancilla B, Blanchette P, Gagnon C, Falardeau P, DiPaolo T (1993) Role of selective D1 and D2 agonists in inducing dyskinesia in drug-naive MPTP monkeys. In: Narabayaski H, Nagatsu T, Yanagisawa N, Mizuno Y (eds) Advances in neurology, vol 60. Raven Press, New York, pp 113-118
4. Billard W, Ruperto V, Crosby G, Iorio LC, Barnett A (1984) Characterization of the binding of [3H]SCH23390, a selective D1 receptor antagonist ligand, in rat striatum. Life Sci 35: 1885-1893
5. Boyson SJ, McGonigle P, Molinoff PB (1986) Quantitative autoradiographic localization of the D1 and D2 subtypes of dopamine receptors in rat brain. J Neurosci 6: 3177-3188
6. Braun AR, Chase TN (1986) Obligatory D-1/D-2 receptor interaction in the generation of dopamine agonist related behaviors. Eur J Pharmacol 131: 301-306
7. Braun AR, Chase TN (1988) Behavioral effects of chronic exposure to selective D-1 and D-2 dopamine receptor agonists [published erratum appears in Eur J Pharmacol 154(3): 351-2]. Eur J Pharmacol 147:441-451
8. Campbell A, Baldessarini RJ, Neumeyer JL (1993) Altered spontaneous behavior and sensitivity to apomorphine in rats following pretreatment with S(+)-aporphines or fluphenazine. Psychopharmacology 111: 351-358
9. Cheetham SC, Kettle CJ, Martin KF, Heal DJ (1995) D1 receptor binding in rat striatum: modification by various D1 and D2 antagonists, but not by sibutramine hydrochloride, antidepressants or treatments which enhance central dopaminergic function. J Neural Transm [Gen Sect]102: 35-46
10. Chipkin RE, McQuade RD, Iorio LC (1987) D1 and D2 binding site upregulation and apomorphine-induced stereotypy. Pharmacol Biochem Behav 28: 477-482
11. Costall B, Naylor RJ (1975) The behavioural effects of dopamine applied intracerebrally to areas of the mesolimbic system. Eur J Pharmacol 32: 87-92
12. Duffy RA, Kaminska G, Chipkin RE, McQuade RD (1992) Selective upregulation of D-1 dopamine receptors following chronic administration of SCH 39166 in primates. Pharmacol Biochem Behav 41: 235-238
13. Elliott PJ, Close SP, Walsh DM, Hayes AG, Marriott AS (1990) Neuroleptic-induced catalepsy as a model of Parkinson's disease. II. Effect of glutamate antagonists. J Neural Transm [PD Sect]2: 91-100
14. Esposito E, Bunney BS (1989) The effect of acute and chronic treatment with SCH 23390 on the spontaneous activity of midbrain dopamine neurons. Eur J Pharmacol 169: 61-66
15. Gerfen CR (1992) The neostriatal mosaic: multiple levels of compartmental organization. J Neural Transm [Suppl] 36: 43-59
16. Gerfen CR, Engber TM (1992) Molecular neuroanatomic mechanisms of Parkinson's disease: a proposed therapeutic approach. Neurol Clin 10: 435-449
17. Giorgi O, Pibiri MG, Loi R, Corda MG (1993) Chronic treatment with SCH 23390 increases the production rate of dopamine D1 receptors in the nigrostriatal system of the rat. Eur J Pharmacol 245: 139-145
18. Gomez-Mancilla B, Bedard PJ (1991) Effect of D1 and D2 agonists and antagonists on dyskinesia produced by L-dopa in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys. J Pharmacol Exp Ther 259: 409-413
19. Grebb JA, Girault JA, Ehrlich M, Greengard P (1990) Chronic treatment of rats with SCH-23390 or raclopride does not affect the concentrations of DARPP-32 or its mRNA in dopamine-innervated brain regions. J Neurochem 55: 204-207
20. Groppetti A, Flauto C, Parati E, Vescovi A, Rusconi L, Parenti M (1986) Dopamine receptor changes in response to prolonged treatment with L-dopa. J Neural Transm 22: 33-40
21. Hallett M (1993) Physiology of basal ganglia disorders: an overview. Can J Neurol Sci 20: 177-183
22. Hess EJ, Albers LJ, Le H, Creese I (1986) Effects of chronic SCH23390 treatment on the biochemical and behavioral properties of D1 and D2 dopamine receptors: potentiated behavioral responses to a D2 dopamine agonist after selective D1 dopamine receptor upregulation. J Pharmacol Exp Ther 238: 846-854
23. Hess EJ, Norman AB, Creese I (1988) Chronic treatment with dopamine receptor antagonists: behavioral and pharmacologic effects on D1 and D2 dopamine receptors. J Neurosci 8: 2361-2370
24. Hornykiewicz O (1975) Parkinsonism induced by dopaminergic antagonists. Adv Neurol 9: 155-164
25. Janssen PA, Awouters FH (1994) Is it possible to predict the clinical effects of neuroleptics from animal data? Part V. From haloperidol and pipamperone to risperidone. Arzneimittelforschung 44: 269-277
26. Janssen PA, Niemegeers CJ, Schellekens KH (1966) Is it possible to predict the clinical effects of neuroleptic drugs (major tranquillizers) from animal data? Arzneimittelforschung 16: 339-246
27. Jenner P, Kerwin R, Rupniak NM, Murugaiah K, Hall MD, Fleminger S, Marsden CD (1983) Long-term adaptive changes in striatal dopamine function in response to chronic neuroleptic intake in rats. J Neural Transm [Suppl] 18: 205-212
28. Jenner P, Rupniak NM, Marsden CD (1985) Differential alteration of striatal D-1 and D-2 receptors induced by the long term administration of haloperidol, sulpride or clozapine to rats. Psychopharmacology [Suppl] 2: 174-181
29. Kelly PH, Seviour PW, Iversen SD (1975) Amphetamine and apomorphine responses in the rat following 6-OHDA lesions of the nucleus accumbens septi and corpus striatum. Brain Res 94: 507-522
30. Klawans HL, Goetz CG, Carvey PM (1983) Animals models of tardive dyskinesia. Clin Neuropharmacol 6: 129-135
31. LaHoste GJ, Marshall JF (1989) Non-additivity of D2 receptor proliferation induced by dopamine denervation and chronic selective antagonist administration: evidence from quantitative autoradiography indicates a single mechanism of action. Brain Res 502: 223-232
32. LaHoste GJ, Marshall JF (1991) Chronic eticlopride and dopamine denervation induce equal nonadditive increases in striatal D2 receptor density: autoradiographic evidence against the dual mechanism hypothesis. Neuroscience 41: 473-481
33. LaHoste GJ, Marshall JF (1992) Dopamine supersensitivity and D1/D2 synergism are unrelated to changes in striatal receptor density. Synapse 12: 14-26
34. Lappalainen J, Hietala J, Koulu M, Seppala T, Sjoholm B, Syvalahti E (1990) Chronic treatment with SCH 23390 and haloperidol: effects on dopaminergic and serotonergic mechanisms in rat brain. J Pharmacol Exp Ther 252: 845-852
35. Lappalainen J, Hietala J, Pohjalainen T, Syvalahti E (1992) Regulation of dopamine D1 receptors by chronic administration of structurally different D1 receptor antagonists: a quantitative autoradiographic study. Eur J Pharmacol 210: 195-200
36. Laruelle M, Jaskiw GE, Lipska BK, Kolachana B, Casanova MF, Kleinman JE, Weinberger DR (1992) D1 and D2 receptor modulation in rat striatum and nucleus accumbens after subchronic and chronic haloperidol treatment. Brain Res 575: 47-56
37. Leysen JE, Gommeren W, Laduron PM (1978) Spiperone, a ligand of choice for neuroleptic receptors. Kinetics and characterization of in vitro binding. Biochem Pharmacol 27: 307-316
38. Lowry OH, Rosebrough NJ, Farr AJ, Randall RJ (1951) Protein measurement with Folin phenol reagent. J Biol Chem 163: 265-275
39. Lublin H, Gerlach J, Peacock L (1993) Chronic treatment with the D1 receptor antagonist, SCH 23390, and the D2 receptor antagonist, raclopride, in cebus monkeys withdrawn from previous haloperidol treatment. Extrapyramidal syndromes and dopaminergic supersensitivity. Psychopharmacology (Berl) 112: 389-397
40. Marin C, Chase TN (1993) Dopamine D1 receptor stimulation but not dopamine D2 receptor stimulation attenuates haloperidol-induced behavioral supersensitivity and receptor up-regulation. Eur J Pharmacol 231: 191-196
41. Marin C, Parashos SA, Kapitzoglou-Logothetis V, Peppe A, Chase TN (1993) D1 and D2 dopamine receptor-mediated mechanisms and behavioral supersensitivity. Pharmacol Biochem Behav 45: 195-200
42. Martin-Iverson MT (1991) Chronic treatment with D1 and D2 dopamine receptor agonists: combined treatments interact to differentially affect brain levels of monoamines. Naunyn Schmiedebergs Arch Pharmacol 344: 281-285
43. Mashurano M, Waddington JL (1986) Stereotyped behaviour in response to the selective D-2 dopamine receptor agonist RU 24213 is enhanced by pretreatment with the selective D-1 agonist SK&F 38393. Neuropharmacology 25: 947-949
44. McGeer PL, McGeer EG, Schurer U, Singh KA (1977) A glutaminergic corticostriatal path. Brain Res 128: 369-373
45. McGonigle P, Boyson SJ, Reuter S, Molinoff PB (1989) Effects of chronic treatment with selective and nonselective antagonists on the subtypes of dopamine receptors. Synapse 3: 74-82
46. Memo M, Pizzi M, Nisoli E, Missale C, Carruba MO, Spano P (1987) Repeated administration of (-)sulpride and SCH 23390 differentially up-regulate D-1 and D-2 dopamine receptor function in rat mesostriatal areas but not in corticallimbic brain regions. Eur J Pharmacol 138: 45-51
47. Meyer ME, Cottrell GA, Van Hartesveldt C (1992) Dopamine D1 antagonists potentiate the durations of bar and cling catalepsy and the dorsal immobility response in rats. Pharmacol Biochem Behav 41: 507-510
48. Molloy AG, Waddington JL (1988) Behavioural responses to the selective D1-dopamine receptor agonist R-SK&F 38393 and the selective D2-agonist RU 24213 in young compared with aged rats. Br J Pharmacol 95: 335-342
49. Murugaiah K, Fleminger S, Hall MD, Theodorou A, Jenner P, Marsden CD (1984) Alterations in different populations of striatal dopamnine receptors produced by 18 months continuous administration of cis- or trans-flupenthixol to rats. Neuropharmacology 23: 599-609
50. Parashos SA, Barone P, Tucci I, Chase TN (1987) Attenuation of D-1 antagonist-induced D-1 receptor upregulation by concomitant D-2 receptor blockade. Life Sci 41: 2279-2284
51. Parashos SA, Barone P, Marin CA, Paraschos AJ, Kapitzoglou-Logothetis V, Chase TN (1989) Haloperidol- and SCH23390-induced dopaminergic supersensitivities are not additive in the rat. Psychopharmacology (Berl) 98: 189-192
52. Parashos SA, Marin C, Chase TN (1989) Synergy between a selective D1 antagonist and a selective D2 antagonist in the induction of catalepsy. Neurosci Lett 105: 169-173
53. Parashos SA, Marin C, Barone P, Kapitzoglou-Logothetis V, Chase TN (1990) Effect of chronic D-1 and/or D-2 dopamine antagonist treatment on SKF 38393-induced non-stereotyped grooming. Psychopharmacology (Berl) 102: 411-413
54. Parenti M, Flauto C, Parati E, Vescovi A, Groppetti A (1986) Differential effect of repeated treatment with L-dopa on dopamine D-1 of D-2 receptors. Neuropharmacology 25: 331-337
55. Paul ML, Graybiel AM, David JC, Robertson HA (1992) D1-like and D2-like dopamine receptors synergistically activate rotation and c-fos expression in the dopamine-depleted striatum in a rat model of Parkinson's disease. J Neurosci 12: 3729-3742
56. Paxinos G, Watson C (1986) The rat brain in stereotaxic coordinates. Academic Press, Orlando
57. Robbins TW, Koob GF (1985) Selective disruption of displacement behavior by lesions of the mesolimbic dopamine system. Nature 285: 409
58. Sanberg PR, Bunsey MD, Giordano M, Norman AB (1988) The catalepsy test: its ups and downs. Behav Neurosci 102: 748-759
59. Schettini G, Ventra C, Florio T, Grimaldi M, Meucci O, Marino A (1992) Modulation by GTP of basal and agonist-stimulated striatal adenylate cyclase activity following chronic blockade of D1 and D2 dopamine receptors: involvement of G proteins in the development of receptor supersensitivity. J Neurochem 59: 1667-1674
60. See RE, Aravagiri M, Ellison GD (1989) Chronic neuroleptic treatment in rats produces persisting changes in GABAA and dopamine D-2, but not dopamine D-1 receptors. Life Sci 44: 229-236
61. Seeman P, Niznik HB (1990) Dopamine receptors and transporters in Parkinson's disease and schizophrenia. FASEB J 4: 2737-2744
62. Seeman P, Bzowej NH, Guan HC, Bergeron C, Reynolds GP, Bird ED, Riederer P, Jellinger K, Tourtellotte WW (1987) Human brain D1 and D2 dopamine receptors in schizophrenia, Alzheimer's, Parkinson's, and Huntington's diseases. Neuropsychopharmacology 1: 5-15
63. Seeman P, Niznik HB, Guan HC, Booth G, Ulpian C (1989) Link between D1 and D2 dopamine receptors is reduced in schizophrenia and Huntington diseased brain. Proc Natl Acad Sci USA 86: 10156-10160
64. Smialowski A (1989) Chronic administration of SCH 23390 enhances spontaneous searching and locomotor activity of rats. An open field study. Behav Brain Res 35: 41-44
65. Stefanini E, Frau M, Gessa GL (1991) Increase in D2 dopamine receptors in the substantia nigra after chronic (-)-sulpiride treatment. Brain Res 555: 340-342
66. Stoof JC, Kebabian JW (1981) Opposing roles for D1 and D2 dopamine receptors in efflux of cyclic AMP from rat neostriatum. Nature 294: 366-368
67. Vaccheri A, Dall'Olio R, Gandolfi O, Roncada P, Montanaro N (1987) Enhanced stereotyped response to apomorphine after chronic D-1 blockade with SCH 23390. Psychopharmacology 91: 394-396
68. Verma A, Kulkarni SK (1992) D1/D2 dopamine and N-methyl-D-aspartate (NMDA) receptor participation in experimental catalepsy in rats. Psychopharmacology 109: 477-483
69. Waddington JL, Gamble SJ (1980) Neuroleptic treatment for a substantial proportion of adult life: behavioral sequallae of 9 months haloperidol administration. Eur J Pharmacol 67: 363-369
70. Walters JR, Bergstrom DA, Carlson JH, Chase TN, Braun AR (1987) D1 dopamine receptor activation required for postsynaptic expression of D2 agonist effects. Science 236: 719-722